Results 41 to 50 of about 724,283 (165)

Systematic Review and Network Meta-Analysis: Comparative Efficacy and Safety of Biosimilars, Biologics and JAK1 Inhibitors for Active Crohn Disease

Frontiers in Pharmacology, 2021
Background: Crohn disease (CD) is a chronic inflammatory disease that affects quality of life. There are several drugs available for the treatment of CD, but their relative efficacy is unknown due to a lack of high-quality head-to-head randomized ...
Guozhi Wu, Guozhi Wu, Guozhi Wu, Yuan Yang, Yuan Yang, Yuan Yang, Min Liu, Min Liu, Yuping Wang, Yuping Wang, Qinghong Guo, Qinghong Guo   +11 more
doaj   +1 more source

Efficacy and safety of biosimilar infliximab CT-P13 in the treatment of psoriasis and psoriatic arthritis: 1-year follow-up [PDF]

Anais Brasileiros de Dermatologia, 2019
Patricia Shu Kurizky, Letícia Oba Galvão, Gladys Aires Martins   +2 more
doaj   +2 more sources

Kontrollierte Einführung des Infliximab-Biosimilars CT-P13 bei Patienten mit Morbus Crohn und Colitis ulcerosa in einer großen deutschen Zentrumskohorte [PDF]

, 2021
Einleitung: Das Infliximab Biosimilar CT-P13 wurde 2013 von der EMA im Rahmen eines Extrapolationsprozesses für die Behandlung von chronisch entzündlichen Darmerkrankungen (CED) ohne Zulassungsstudien genehmigt.
Röder, Helene
core   +1 more source

The Role of Infliximab Biosimilar CT-P13 in Inflammatory Bowel Disease [PDF]

Journal of Exploratory Research in Pharmacology, 2017
The advent of targeted biologic therapies for debilitating disorders such as Crohn’s disease (CD) and Ulcerative Colitis (UC) has changed management and significantly improved outcomes. However, biologic agents are expensive, and the introduction of biosimilar medications for the treatment of inflammatory bowel diseases presents a lower-cost ...
Devika Kapuria, Rajiv Chhabra
openaire   +1 more source

Beyond Radical Emitters: Hot‐Exciton Electroluminescence From Singlet Diradicaloids

Angewandte Chemie, EarlyView.
The first hot‐exciton mechanism in a singlet diradicaloid is demonstrated in a polychlorinated Thiele hydrocarbon‐based organic light‐emitting transistor. Reverse intersystem crossing involving the T2 and bright singly excited states enables electroluminescence beyond the 25% spin‐statistical limit, leading to remarkable external quantum efficiency ...
Mario Prosa, Eugenio Lunedei, Michele Orza, Davide Mesto, Roberto Cantoni, Francesco Reginato, Angela Punzi, Arthur R. J. Barreto, Yasi Dai, Benedetta Carlotti, Fabrizia Negri, Stefano Toffanin, Davide Blasi   +12 more
wiley   +2 more sources

Degradable Alternating Copolymers With Strained Cyclobutane Backbones via Photocontrolled RAFT Polymerization

Angewandte Chemie, EarlyView.
A photocontrolled RAFT strategy enables the alternating copolymerization of 1,3‐disubstituted bicyclo[1.1.0]butanes with electron‐deficient comonomers, affording well‐defined copolymers bearing strained cyclobutane backbones. A high degree of alternation, tunable molecular weights, and excellent end‐group fidelity are achieved through a CTA‐mediated ...
Xia Hu, Hongsik Kim, Lianqian Wu, Yi Jiang, Tae‐Lim Choi   +4 more
wiley   +2 more sources

Patients with Ankylosing Spondylitis Can Maintain Clinical and Functional Improvement after Switching from Infliximab Reference Product to Infliximab Biosimilar (REMSIMA): 12 Months Comparative Open-Label Study

Journal of Clinical Rheumatology and Immunology, 2022
Objective: Efficacy, tolerance, and safety of infliximab biosimilar are the same as infliximab reference product (RP) in the management of ankylosing spondylitis (AS) patients previously were on infliximab RP.
Abdulsatar J. Mathkhor, Ali Altaqi, Abdulnasser Abdullah, Amer Khudhairy   +3 more
doaj   +1 more source

Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease [PDF]

, 2021
BACKGROUND: Patients suffering from inflammatory bowel diseases (IBD) and treated with originator infliximab are increasingly being switched to biosimilars. Some patients, however, are "reverse switched" to treatment with the originator.
Mahmmod, Shaden, Hoentjen, Frank, Lutgens, Maurice W M D, Gerard Dijkstra, Frank Hoentjen, Dijkstra, Gerard, Lisa J T Smits, Shaden Mahmmod, Ad A van Bodegraven, Oldenburg, Bas, Smits, Lisa J T, van der Meulen-de Jong, Andrea E, Nofel Mahmmod, Fidder, Herma H, Adriaan C I T L Tan, Tan, Adriaan C I T L, Johannes P D Schultheiss, Andrea E van der Meulen–de Jong, Herma H Fidder, Dijkstra, Gerard; id_orcid, Bas Oldenburg, Maurice W M D Lutgens, Gilissen, Lennard P L, Mahmmod, Nofel, Schultheiss, Johannes P D, van Bodegraven, Ad A, Lennard P L Gilissen   +26 more
core   +4 more sources

Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease. [PDF]

Dig Dis Sci, 2020
Biosimilar approval, such as Inflectra™ (CT-P13) for treating ulcerative colitis (UC) and Crohn's disease (CD), has reduced direct drug costs. Though clinicians are comfortable with biosimilar use in treatment-naïve patients, there are concerns in some jurisdictions that there are insufficient data from well-controlled trials to support non-medical ...
Bernard EJ, Fedorak RN, Jairath V.
europepmc   +4 more sources

Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe [PDF]

Expert Review of Clinical Immunology, 2015
Biosimilars are drugs developed to be highly similar to their originator biologic (or ‘reference medicinal product’) with no clinically meaningful differences in purity, efficacy or safety. Production of biologics and biosimilars is highly complex and sensitive, with any change in manufacturing process having a potential impact on efficacy and safety ...
Ulf, Müller-Ladner, SeungSuh, Hong, Choongseob, Oh, Peter, Taylor   +3 more
openaire   +2 more sources